{
  "thread": {
    "uuid": "e12884cb5281ee10a7428c532aff48f5a6e6cf78",
    "url": "https://finance.sina.com.cn/roll/2025-07-31/doc-infiitzy9208143.shtml",
    "site_full": "finance.sina.com.cn",
    "site": "sina.com.cn",
    "site_section": "https://finance.sina.cn",
    "site_categories": [
      "tech",
      "top_news_hk",
      "top_news_sg",
      "top_news_tw",
      "top_news"
    ],
    "section_title": "新浪财经_金融信息服务商",
    "site_title": null,
    "title": "恒瑞启动哮喘新药首个 III 期临床|哮喘_新浪财经_新浪网",
    "title_full": "恒瑞启动哮喘新药首个 III 期临床|哮喘_新浪财经_新浪网",
    "published": "2025-07-31T07:06:00.000+03:00",
    "replies_count": 0,
    "participants_count": 0,
    "site_type": "news",
    "country": "CN",
    "main_image": "",
    "performance_score": 0,
    "domain_rank": 236,
    "domain_rank_updated": "2025-06-03T00:00:00.000+03:00",
    "licensing_agency": [],
    "social": {
      "facebook": {
        "likes": 0,
        "comments": 0,
        "shares": 0
      },
      "vk": {
        "shares": 0
      }
    }
  },
  "uuid": "e12884cb5281ee10a7428c532aff48f5a6e6cf78",
  "url": "https://finance.sina.com.cn/roll/2025-07-31/doc-infiitzy9208143.shtml",
  "ord_in_thread": 0,
  "author": null,
  "published": "2025-07-31T07:06:00.000+03:00",
  "title": "恒瑞启动哮喘新药首个 III 期临床|哮喘_新浪财经_新浪网",
  "text": "（来源：求实药社）\n7 月 30 日，药物临床试验登记与信息公示平台官网显示，恒瑞 医药登记了一项 评估 SHR-1905 注射液在伴重度未控制哮喘患 者的有效性及安全 性的 Ⅲ 期临床研究 （ SHR-1905-302，登记号： CTR20252988 ） 。\n药物临床试验登记与信息公示平台官网\n这是一项 多中心、随机、双盲、安慰剂对照、平行设计 Ⅲ 期临床研究，计划入组 408 名受试者，随机分组接受 SHR-1905 注射液、安慰剂治疗。 主要研究者是 广州医科大学附属第一医院主任医师钟南山 和副主任医师 杨新艳。\n主要终点是 哮喘年急性发作率 （AAE R） ，次要终点包括 第 48 周使用支气管舒张剂前 （Pre-BD） 第一秒用力呼气容积 （FEV1） 较基线变化、 呼出气一氧化氮 （FeNO） 较基线变化等。\nSHR-1905 为恒瑞自主研发的一款胸腺基质淋巴细胞生成素 （TSLP） 单克隆抗体，可以阻断炎症细胞因子的释放，抑制下游炎症信号的传导， 最终改善炎症状态并控制疾病进展。\n2023 年 8 月，恒瑞与美国 One Bio （后叫 Aiolos Bio） 达成协议，将 SHR-1905 注射液项目有偿许可给后者， 首付款和近期里程碑付款 2500 万美元，研发和销售里程碑付款不超过 10.25 亿美元。2024 年初，GSK 以 14 亿美元收购 Aiolos Bio 囊获了该产品。\n文章内容仅供参考，不构成投资建议。投资者据此操作，风险自担, 关于对文中陈述、观点判断保持中立，不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部。",
  "highlightText": "",
  "highlightTitle": "",
  "highlightThreadTitle": "",
  "language": "chinese",
  "sentiment": "positive",
  "categories": [
    "Health",
    "Science and Technology",
    "Economy, Business and Finance"
  ],
  "topics": [
    "Health->health treatment and procedure",
    "Health->drug rehabilitation",
    "Health->medical test",
    "Science and Technology->medical research",
    "Science and Technology->biotechnology",
    "Economy, Business and Finance->healthcare industry",
    "Economy, Business and Finance->products and services",
    "Economy, Business and Finance->business reporting and performance"
  ],
  "ai_allow": true,
  "has_canonical": false,
  "breaking": null,
  "webz_reporter": false,
  "external_links": [],
  "external_images": [],
  "internal_images": [],
  "entities": {
    "persons": [],
    "locations": [],
    "organizations": []
  },
  "syndication": {
    "syndicated": null,
    "syndicate_id": null,
    "first_syndicated": false
  },
  "trust": {
    "categories": [],
    "top_news": [
      "top_news_hk",
      "top_news_sg",
      "top_news_tw",
      "top_news"
    ],
    "bias": null,
    "source": {
      "type": null,
      "city": null,
      "state": null,
      "country": null,
      "domain_type": null,
      "agency": null,
      "organization_name": null
    }
  },
  "rating": null,
  "crawled": "2025-07-31T08:20:44.897+03:00",
  "updated": "2025-08-01T09:05:41.000+03:00"
}